Switch to:
More From Other Websites
3 Key Therapeutic Segments Drive Branded Revenues Apr 01 2015
Analyzing Pfizer’s Research and Development Apr 01 2015
Dyax Soars As Rare-Disease Drug Wows Wall Street Apr 01 2015
Pfizer’s Global Established Pharmaceutical Segment Apr 01 2015
Teva Announces FDA Approval of ProAir® RespiClick Apr 01 2015
8:01 am Teva Pharma announces the FDA has approved ProAir RespiClick Apr 01 2015
Teva Announces FDA Approval of ProAir® RespiClick Apr 01 2015
Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen Mar 31 2015
Teva Reinforces Leadership Position in CNS with Acquisition of Auspex Mar 31 2015
5 Stocks, 5 trades: CHTR, DHI, IBM, TEVA, & CBG Mar 31 2015
Analyst Sees No Rival Bids For Auspex Pharmaceuticals Mar 31 2015
Hedge fund Tigershark Partners to close doors Mar 31 2015
Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come Mar 31 2015
Healthcare ETFs Rally on Monday Merger Mania - ETF News And Commentary Mar 31 2015
Teva Expands Hypertension Line with Launch of Generic Exforge® Tablets in the United States Mar 31 2015
Teva Expands Hypertension Line with Launch of Generic Exforge® Tablets in the United States Mar 31 2015
Analysts' Actions -- IAC/InterActiveCorp, Priceline, Reliance Steel, Teva and More Mar 31 2015
Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Mar 31 2015
Teva Pharma upgraded by Oppenheimer Mar 31 2015
Five Firms Take Lead in Health-Care Deal Flurry: Business of Law Mar 30 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK